SES AI Corporation received a notice from the New York Stock Exchange (NYSE) on July 17, 2026, stating it is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The non-compliance occurred because the average closing price of its Class A common stock was less than $1.00 per share over a period of 30 consecutive trading days. This average closing price is the minimum required to maintain continued listing on the NYSE.

SES AI plans to respond to the NYSE within 10 business days of receiving the notice. The response will outline its intent to cure the deficiency and return to compliance with the NYSE's continued listing requirements. The company's Class A common stock will continue to be listed and trade on the NYSE during this period, provided it complies with other NYSE continued listing standards.

To regain compliance, SES AI must meet specific price criteria within a six-month period following the receipt of the notice. The company can cure the deficiency if, on the last trading day of any calendar month during this period, its Class A common stock has a closing share price of at least $1.00. Additionally, the average closing share price must be at least $1.00 over the 30 trading-day period ending on that last trading day.

Under NYSE rules, if SES AI determines that curing the stock price deficiency requires an action needing stockholder approval at its next annual meeting, the price condition will be considered cured differently. In this scenario, the price must promptly exceed $1.00 per share and remain above that level for at least the following 30 trading days.

Compliance Timeline and Conditions

The following table outlines the conditions for SES AI to regain compliance with the NYSE listing standards:

Faruqi & Faruqi, LLP is reminding investors who purchased SES AI Corporation securities between January 29, 2025, and March 4, 2026, of the June 26, 2026 deadline to seek appointment as lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that the company issued materially false and misleading statements regarding its business prospects, overstating results from deals with entities that had limited or no operations. Investors are advised that serving as lead plaintiff is not required to participate in any recovery, but the deadline to move for this role is fast approaching.

The complaint alleges that SES AI created an appearance of revenue by purchasing services in exchange for purchases of Molecular Universe and failed to disclose material logistics constraints in the fourth quarter of 2025. These constraints reportedly affected Q4 2025 revenues and confirmed lower than expected 2026 revenue guidance. On March 4, 2026, SES AI reported its fourth quarter and full year 2025 financial results, disclosing that logistics constraints delayed shipments, pushing approximately $1.5 million of expected revenue into the first quarter of 2026. Following this news, the company's stock price fell $0.63 per share, or 36.84%, to close at $1.08 per share on March 5, 2026.

Case Details

Faruqi & Faruqi, LLP joins other firms investigating the matter, including The Gross Law Firm, Bernstein Liebhard LLP, and The Rosen Law Firm. The case, titled Patel v. SES AI Corporation, et al., is Case No. 26-cv-11894.